ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Zoetis Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$79.59+0.21 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $33.24B
- P/E (TTM)
- 13.1
- Dividend yield
- 2.55%
Zoetis Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $1.27B | $1.09B | $1.24B | $1.32B | $1.36B | $1.18B | $1.26B | $1.35B | $1.31B | $1.16B | $1.21B | $1.17B | 51.3% | -6.6% |
| International | $1.17B | $1.15B | $1.12B | $1.06B | $1.09B | $985.00M | $1.04B | $1.02B | $1.04B | $1.01B | $982.00M | $956.00M | 47.5% | +8.1% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total products and services | $2.44B | $2.24B | $2.36B | $2.38B | $2.44B | $2.17B | $2.30B | $2.37B | $2.34B | $2.17B | $2.19B | $2.13B | 98.8% | -0.1% |
| Companion animal | $1.71B | $1.52B | $1.60B | $1.65B | $1.79B | $1.54B | $1.57B | $1.61B | $1.65B | $1.45B | $1.45B | $1.41B | 69.2% | -4.6% |
| Dogs and Cats | $1.63B | $1.44B | – | $1.59B | $1.72B | $1.48B | – | $1.55B | $1.58B | $1.38B | – | $1.35B | 66.2% | -4.9% |
| Livestock | $731.00M | $720.00M | $756.00M | $725.00M | $651.00M | $627.00M | $726.00M | $758.00M | $694.00M | $720.00M | $745.00M | $716.00M | 29.6% | +12.3% |
| Parasiticides | $698.00M | $586.00M | $542.00M | $564.00M | $660.00M | $572.00M | $519.00M | $530.00M | $600.00M | $504.00M | $482.00M | $465.00M | 28.3% | +5.8% |
| Vaccines | $521.00M | $519.00M | $512.00M | $496.00M | $510.00M | $439.00M | $462.00M | $468.00M | $445.00M | $452.00M | $463.00M | $449.00M | 21.1% | +2.2% |
| Dermatology | $398.00M | $349.00M | $429.00M | $472.00M | $473.00M | $379.00M | $421.00M | $453.00M | $418.00M | $363.00M | $379.00M | $397.00M | 16.1% | -15.9% |
| Cattle | $390.00M | $392.00M | $415.00M | $399.00M | $323.00M | $341.00M | $399.00M | $391.00M | $350.00M | $391.00M | $401.00M | $374.00M | 15.8% | +20.7% |
| Anti-infectives | $244.00M | $241.00M | $284.00M | $284.00M | $222.00M | $238.00M | $281.00M | $274.00M | $264.00M | $281.00M | $261.00M | $264.00M | 9.9% | +9.9% |
| Pain and sedation | $217.00M | $203.00M | $209.00M | $204.00M | $223.00M | $207.00M | $217.00M | $219.00M | $221.00M | $194.00M | $194.00M | $147.00M | 8.8% | -2.7% |
| Other pharmaceutical | $168.00M | $158.00M | $188.00M | $178.00M | $175.00M | $158.00M | $180.00M | $169.00M | $153.00M | $156.00M | $164.00M | $166.00M | 6.8% | -4.0% |
| Animal health diagnostics | $123.00M | $117.00M | $111.00M | $110.00M | $110.00M | $104.00M | $100.00M | $101.00M | $103.00M | $82.00M | $92.00M | $95.00M | 5.0% | +11.8% |
| Swine | $117.00M | $123.00M | $125.00M | $111.00M | $118.00M | $105.00M | $128.00M | $131.00M | $130.00M | $127.00M | $139.00M | $129.00M | 4.7% | -0.8% |
| Poultry | $115.00M | $118.00M | $117.00M | $106.00M | $104.00M | $106.00M | $117.00M | $139.00M | $132.00M | $139.00M | $127.00M | $127.00M | 4.7% | +10.6% |
| Fish | $83.00M | $66.00M | $81.00M | $78.00M | $81.00M | $55.00M | $65.00M | $70.00M | $62.00M | $45.00M | $62.00M | $57.00M | 3.4% | +2.5% |
| Horses | $74.00M | $76.00M | $6.08B | $66.00M | $71.00M | $64.00M | $5.80B | $58.00M | $68.00M | $66.00M | $5.09B | $60.00M | 3.0% | +4.2% |
| Other non-pharmaceutical | $70.00M | $66.00M | $70.00M | $64.00M | $68.00M | $71.00M | $65.00M | $62.00M | $65.00M | $61.00M | $61.00M | $61.00M | 2.8% | +2.9% |
| Contract manufacturing & human health | $29.00M | $23.00M | $30.00M | $23.00M | $33.00M | $30.00M | $21.00M | $21.00M | $18.00M | $20.00M | – | – | 1.2% | -12.1% |
| Sheep and other | $26.00M | $21.00M | $18.00M | $31.00M | $25.00M | $20.00M | $17.00M | $27.00M | $20.00M | $18.00M | $16.00M | $29.00M | 1.1% | +4.0% |
| Medicated feed additives | – | – | $12.00M | $5.00M | $5.00M | $5.00M | $51.00M | $91.00M | $74.00M | $77.00M | $97.00M | $86.00M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total geographical area | $2.44B | $2.24B | $2.36B | $2.38B | $2.44B | $2.17B | $2.30B | $2.37B | $2.34B | $2.17B | $2.19B | $2.13B | 98.8% | -0.1% |
| United States | $1.27B | $1.09B | $1.24B | $1.32B | $1.36B | $1.18B | $1.26B | $1.35B | $1.31B | $1.16B | $1.21B | $1.17B | 51.3% | -6.6% |
| Other emerging markets | $269.00M | $291.00M | $212.00M | $228.00M | $223.00M | $238.00M | $195.00M | $220.00M | $222.00M | $228.00M | $179.00M | $187.00M | 10.9% | +20.6% |
| Other developed markets | $187.00M | $169.00M | $182.00M | $164.00M | $175.00M | $133.00M | $151.00M | $148.00M | $138.00M | $127.00M | $138.00M | $127.00M | 7.6% | +6.9% |
| Brazil | $103.00M | $90.00M | $112.00M | $100.00M | $93.00M | $81.00M | $113.00M | $101.00M | $99.00M | $101.00M | $117.00M | $101.00M | 4.2% | +10.8% |
| Australia | $94.00M | $89.00M | $84.00M | $87.00M | $83.00M | $79.00M | $80.00M | $83.00M | $83.00M | $73.00M | $75.00M | $84.00M | 3.8% | +13.3% |
| Canada | $72.00M | $73.00M | $80.00M | $70.00M | $71.00M | $70.00M | $75.00M | $66.00M | $75.00M | $61.00M | $72.00M | $63.00M | 2.9% | +1.4% |
| United Kingdom | $72.00M | $78.00M | $89.00M | $82.00M | $81.00M | $74.00M | $84.00M | $80.00M | $73.00M | $77.00M | $68.00M | $78.00M | 2.9% | -11.1% |
| Germany | $69.00M | $59.00M | $65.00M | $62.00M | $57.00M | $55.00M | $59.00M | $57.00M | $58.00M | $51.00M | $54.00M | $50.00M | 2.8% | +21.1% |
| China | $62.00M | $63.00M | $50.00M | $45.00M | $67.00M | $55.00M | $65.00M | $61.00M | $68.00M | $76.00M | $65.00M | $69.00M | 2.5% | -7.5% |
| Mexico | $47.00M | $48.00M | $44.00M | $41.00M | $39.00M | $35.00M | $40.00M | $39.00M | $46.00M | $44.00M | $43.00M | $42.00M | 1.9% | +20.5% |
| Spain | $43.00M | $40.00M | $37.00M | $38.00M | $40.00M | $29.00M | $30.00M | $35.00M | $33.00M | $32.00M | $28.00M | $30.00M | 1.7% | +7.5% |
| Japan | $41.00M | $35.00M | $39.00M | $34.00M | $43.00M | $32.00M | $38.00M | $33.00M | $39.00M | $37.00M | $38.00M | $34.00M | 1.7% | -4.7% |
| France | $40.00M | $37.00M | $52.00M | $40.00M | $42.00M | $39.00M | $45.00M | $36.00M | $34.00M | $41.00M | $40.00M | $34.00M | 1.6% | -4.8% |
| Italy | $40.00M | $39.00M | $35.00M | $35.00M | $37.00M | $30.00M | $34.00M | $31.00M | $36.00M | $28.00M | $34.00M | $26.00M | 1.6% | +8.1% |
| Chile | $34.00M | $38.00M | $40.00M | $29.00M | $34.00M | $35.00M | $30.00M | $31.00M | $31.00M | $31.00M | $31.00M | $31.00M | 1.4% | 0.0% |
| Contract manufacturing & human health | – | – | – | – | – | – | – | $21.00M | $18.00M | $20.00M | – | $21.00M | – | – |
From the segment and revenue-disaggregation notes of Zoetis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.